Patterns of amphotericin B killing kinetics against seven Candida species

被引:103
作者
Cantón, E
Pemán, J
Gobernado, M
Viudes, A
Espinel-Ingroff, A
机构
[1] Univ Valencia, Hosp La Fe, Ctr Invest, Unidad Microbiol Expt, Valencia 46009, Spain
[2] Univ Valencia, Hosp La Fe, Microbiol Serv, Valencia 46009, Spain
[3] Virginia Commonwealth Univ, Med Coll Virginia, Div Infect Dis, Richmond, VA 23298 USA
关键词
D O I
10.1128/AAC.48.7.2477-2482.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In a previous study tolerance to amphotericin B (AMB) was found among Candida parapsilosis and C. dubliniensis strains by seeding the Whole volumes of wells used for MIC determinations, and minimum fungicidal concentrations (MFC) for non-C. albicans Candida strains were demonstrated to be above the levels safely achievable in serum. As an extension of that study, we performed time-kill assays with 26 blood culture isolates (6 C. albicans, 5 C. parapsilosis, 5 C. krusei, 4 C. glabrata, 3 C. lusitaniae, and 3 C. tropicalis isolates), 3 oropharyngeal C. dubliniensis isolates, 3 AMB-susceptible isolates (ATCC 90028, ATCC 22019, ATCC 6254), and 6 AMB-resistant isolates (ATCC 200955, ATCC 200956, ATCC 200950, ATCC 200951, ATCC 200952, ATCC 200953) using RPMI 1640 medium and 0.12 to 32 mug of AMB per ml and determined the numbers of CFU per milliliter at 0, 2, 4, 8, 12, 24, and 48 h. MFCs and time-kill patterns were species specific (MFCs, less than or equal to1 mug/ml for all C. dubliniensis and C. albicans isolates except AMB-resistant strain ATCC 200955; MFCs, 2 to >16 mug/ml for the other isolates). The times required to reach the fungicidal endpoint (99.9% killing) at four times the MIC were 2 h for C. albicans and C. dubliniensis, 16 h for C. glabrata, 24 h for C. parapsilosis and C. lusitaniae, and greater than or equal to40 h for C. tropicalis and C. krusei. The killing rate increased as the AMB concentration was increased up to 2 mug/ml. The highest killing rates were achieved for C. albicans, C. dubliniensis, and C. lusitaniae, while viable C. tropicalis, C. krusei, and C. parapsilosis cells were present after 48 h (MICs, less than or equal to2 mug/ml) when AMB was used at 2 mug/ml. Time-kill curves and MFCs can detect viable cells after 48 h when AMB is used at greater than or equal to2 mug/ml. The failure of AMB treatment could be due to its poor killing activity against some species at the concentrations reached in patients' serum.
引用
收藏
页码:2477 / 2482
页数:6
相关论文
共 34 条
[1]   Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans [J].
Bekersky, I ;
Fielding, RM ;
Dressler, DE ;
Lee, JW ;
Buell, DN ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :828-833
[2]   Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans [J].
Burgess, DS ;
Hastings, RW ;
Summers, KK ;
Hardin, TC ;
Rinaldi, MG .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (01) :13-18
[3]   Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species [J].
Cantón, E ;
Pemán, J ;
Viudes, A ;
Quindós, G ;
Gobernado, M ;
Espinel-Ingroff, A .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 45 (03) :203-206
[4]  
Canton Emilia, 1999, Revista Iberoamericana de Micologia, V16, P82
[5]   Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America SENTRY Antimicrobial Surveillance Program, 1997-2000 [J].
Diekema, DJ ;
Pfaller, MA ;
Jones, RN .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (06) :412-418
[6]  
DRUZ DJ, 1978, AM J MED SCI, V276, P77
[7]   Overview of the lipid formulations of amphotericin B [J].
Dupont, B .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 :31-36
[8]   Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods [J].
Ernst, EJ ;
Yodoi, K ;
Roling, EE ;
Klepser, ME .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :578-581
[9]   AMPHOTERICIN-B SERUM CONCENTRATIONS DURING THERAPY [J].
FIELDS, BT ;
BATES, JH ;
ABERNATHY, RS .
APPLIED MICROBIOLOGY, 1970, 19 (06) :955-+
[10]  
GRILLOT R, 2000, REV IBEROAM MICOL, V17, pS144